High-intensity interval training for patients with lupus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effects of high-intensity interval training (HIIT) combined with resistance exercises in patients with systemic lupus erythematosus (SLE). It is a randomized controlled trial that aims to assess improvements in aerobic capacity, muscle function, disease activity, and quality of life over a six-month period. Participants will undergo three months of supervised training followed by three months of self-training with support. The study also seeks to understand patient experiences and the impact of exercise on inflammatory markers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years old
* Fulfilment of the 1982 American College of Rheumatology (ACR) criteria; or 2012 Systemic Lupus International Collaborating Clinics (SLICC/ACR-Damage Index (DI)) classification criteria; or EULAR/ACR criteria; or patients that have received the diagnosis SLE on clinical grounds
* Low to moderate disease activity, for example defined as a score of ≤5 in the clinical version of the SLE Disease Activity Index 2000 (SLEDAI-2K), i.e., excluding the serological descriptors (anti-dsDNA positivity and low complement levels)
* Low/minimal or no organ damage, for example defined as a score of ≤3 in the SLICC/ACR DI
* Stable pharmacological treatment
* The ability to perform a maximal ergometercycle exercise test
* Be able to read and understand Swedish

Exclusion Criteria:

* Symptoms or signs of cerebro-vascular disease, pulmonary embolus, pulmonary hypertension, pulmonary fibrosis, cardiovascular disease, angina pectoris, myocardial infarction, dyspnea at rest, uncontrolled blood pressure and uncontrolled diabetes within one year prior to study entry. Chronic kidney disease with
* Patients who fulfil the absolute contraindications for maximal exercise testing according to American Heart Association
* Patients who cannot perform a maximal ergometercycle exercise test due to the disease
* Diseases or other conditions that strongly reduce the ability to exercise or that exercise is not recommended
* Patients who perform regular aerobic fitness training and muscle strength exercise sessions at fixed times, \>1 time/week
* Pregnancy

Where it's running

• Carina Boström
  Stockholm, Huddinge, Sweden Recruiting

Study contacts

• Principal investigator: Carina M Boström, Dr — Karolinska Institutet
• Study coordinator: Carina M Boström, Dr
• Email: carina.bostrom@ki.se
• Phone: 046 0722006321

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Anifrolumab in Chinese patients with active moderate-to-severe SLE

  This study tests whether adding anifrolumab to standard care helps Chinese adults with active moderate-to-severe SLE achieve remission and reduces glucocorticoid use.

  Recruiting at 25 sites Phase 3 AstraZeneca · Beijing and 73 other locations · NCT07751848

• Cevostamab in systemic lupus erythematosus with or without active lupus nephritis

  This study tests cevostamab in people with systemic lupus erythematosus, with or without active lupus nephritis, to see how safe it is and how the body handles it when added to standard care.

  Recruiting at 11 sites Phase 1 Genentech, Inc. · Parkville, Victoria and 10 other locations · NCT07629583

• Nipocalimab for adults with moderate to severe systemic lupus erythematosus

  This trial tests nipocalimab versus placebo in adults with moderate to severe lupus to see if it reduces disease activity and symptoms.

  Recruiting at 270 sites Phase 3 Janssen Research & Development, LLC · Beverly Hills, California and 271 other locations · NCT07438496

• Disease activity and quality of life in adults with SLE starting subcutaneous anifrolumab

  This project will try to see how subcutaneous anifrolumab works for adults with lupus by collecting clinical measurements and patient-reported outcomes in routine care.

  Recruiting at 21 sites AstraZeneca · Altenburg and 20 other locations · NCT07424261

• Anifrolumab to achieve LLDAS5 in people with systemic lupus erythematosus

  This study tests whether anifrolumab helps people with systemic lupus erythematosus reach and keep low disease activity while staying on 5 mg/day or less of corticosteroids.

  Recruiting at 14 sites AstraZeneca · Monserrato, CA and 21 other locations · NCT07330245

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.